Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting NCT07684144 Sponsor: Amgen Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Not Yet Recruiting

NCT07684144
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must have signed a consent form agreeing to follow the requirements of the trial.
  • The person must have completed the Week 72 visit in the previous related study (Study 20210184).
  • The person must not have permanently stopped taking the study treatment during that previous study.
  • The person must be enrolled in this trial within 7 days of their Week 72 visit in the previous study.
  • The person must agree to use specific birth control methods during the trial and for 16 weeks after their last dose of the study treatment.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have surgery, an endoscopy, or a device-based procedure planned for obesity treatment during the trial.
  • People with a body mass index (BMI) of 18.5 or below (confirm with trial site).
  • People who are known to have an allergy or sensitivity to any ingredient in the study treatment.
  • People with a history of a condition called ischemic optic neuropathy, which involves reduced blood flow to the optic nerve.
  • People who were diagnosed with cancer during the previous study, except for certain types treated with the intent to cure — including certain non-melanoma skin cancers, breast ductal carcinoma in situ, cervical carcinoma in situ, and prostate cancer in situ.
  • People newly diagnosed during the previous study with a hormonal condition called multiple endocrine neoplasia syndrome type 2, or who have a close family member (parent, sibling, or child) with a history of a specific type of thyroid cancer called medullary thyroid carcinoma.
  • People who scored 15 or higher on a depression screening questionnaire (PHQ-9) at their Week 72 visit in the previous study.
  • People who reported certain levels of suicidal thoughts or any suicidal behaviour on a standardised assessment scale (C-SSRS) at their Week 72 visit in the previous study.
  • People who, in the opinion of the trial investigator, are unlikely to be able to complete all required trial procedures and follow all trial requirements.
  • People with a history of any other significant health condition, disorder, or disease — including known drug or alcohol misuse or eating disorders — that the investigator believes could put the person at risk.
  • People who are currently pregnant, breastfeeding, or planning to become pregnant or breastfeed during the trial or within 16 weeks after the last dose of the study treatment.
  • People who have a major surgical procedure planned during the trial.
  • People who work directly at the trial site or who are an immediate family member (spouse, parent, child, or sibling) of someone who does.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026

If you need support right now

This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.

If you or someone else is in immediate danger, call 000.

  • Lifeline — 24/7 crisis support: 13 11 14
  • Suicide Call Back Service — 24/7 counselling: 1300 659 467
  • 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
  • Beyond Blue — 24/7 mental health support: 1300 22 4636
  • Kids Helpline — 24/7, free and private for anyone aged 5 to 25: 1800 55 1800
  • headspace — mental health support for 12 to 25 year olds: headspace.org.au
  • Emergency: 000

Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.

Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.

Contact this trial

Principal Investigator: MD, Amgen

Phone: 866-572-6436

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
29 July 2026
Est. completion
26 December 2027

Primary endpoints

Percent Change in Body Weight from Baseline of the Parent Trial (20210184); Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov